GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Travere Therapeutics Inc (NAS:TVTX) » Definitions » Short-Term Debt

TVTX (Travere Therapeutics) Short-Term Debt : $68.6 Mil (As of Sep. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Travere Therapeutics Short-Term Debt?

Travere Therapeutics's Short-Term Debt for the quarter that ended in Sep. 2024 was $68.6 Mil.

Travere Therapeutics's quarterly Short-Term Debt stayed the same from Mar. 2024 ($0.0 Mil) to Jun. 2024 ($0.0 Mil) but then increased from Jun. 2024 ($0.0 Mil) to Sep. 2024 ($68.6 Mil).


Travere Therapeutics Short-Term Debt Historical Data

The historical data trend for Travere Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Travere Therapeutics Short-Term Debt Chart

Travere Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Travere Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 68.60

Travere Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Travere Therapeutics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Travere Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Travere Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
3611 Valley Centre Drive, Suite 300, San Diego, CA, USA, 92130
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
Executives
Sandra Calvin officer: VP, Corp Controller and CAO 3611 VALLEY CENTER DRIVE, SUITE 300, SAN DIEGO CA 92130
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Jeffrey A Meckler director 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
Jula Inrig officer: Chief Medical Officer C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
William E. Rote officer: Senior Vice President, R&D C/O RETROPHIN, INC., 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Christopher R. Cline officer: Chief Financial Officer C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, STE 300, SAN DIEGO CA 92130
Eric M Dube director, officer: Chief Executive Officer 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Peter Heerma officer: Chief Commercial Officer C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Elizabeth E Reed officer: SVP, GC & Corporate Secretary 9050 CAMINO SANTA FE, SAN DIEGO CA 92121
Laura Clague officer: Chief Financial Officer 370 PARK RANCH PLACE, ESCONDIDO CA 92025
Steve Aselage director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Brinkley Ruth Williams director C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Noah L. Rosenberg officer: Chief Medical Officer C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Neil F. Mcfarlane officer: Chief Operating Officer C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130